Cannabis Rescheduling
The DEA's formal process to move cannabis from Schedule I to Schedule III under the Controlled Substances Act — the largest near-term catalyst for the sector.
Definition
Cannabis rescheduling refers to the U.S. Drug Enforcement Administration's (DEA) formal administrative process to reclassify cannabis from Schedule I (no accepted medical use, high abuse potential) to Schedule III (moderate to low abuse potential, accepted medical use) under the Controlled Substances Act. The process began in 2022 when HHS recommended rescheduling based on its eight-factor scientific review, and was formally initiated by the DEA's Notice of Proposed Rulemaking in May 2024. A final rule would not legalize cannabis federally but would remove the 280E tax penalty for state-legal operators and unlock institutional banking access.
Also known as: Schedule III rescheduling, DEA rescheduling, Cannabis reclassification
Why It Matters for Investors
Rescheduling is the highest-leverage near-term catalyst for U.S. cannabis equities. Eliminating 280E would free hundreds of millions in annual cash flow across the MSO universe — Cresco, Trulieve, Curaleaf, and Green Thumb alone disclose $200M+ in combined 280E-attributable tax annually. Most institutional cannabis funds and SAFE-banking-conditioned capital remain on the sidelines pending the final rule.
Examples in Practice
- The DEA's May 2024 Notice of Proposed Rulemaking triggered a +30% sector rally over two trading sessions.
- Final rule timing is the most-asked question on Q3/Q4 2026 MSO earnings calls.
Track the 88 cannabis equities behind every term in this glossary
Get the daily CIN brief — pre-open, midday, and close. Always free.
Get the Brief